Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)
Phase 2
35
about 4.4 years
18+
1 site in TX
What this study is about
Researchers are testing a treatment with pembrolizumab, docetaxel, and cisplatin or carboplatin as a single treatment for advanced squamous cell carcinoma of the nasal cavity/paranasal sinuses. The trial will last approximately 1609 days and enrolls adults.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Carboplatin
- 2.Take Cisplatin
- 3.Take Docetaxel
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
carboplatin, cisplatin (Platinum chemotherapy; crosslinks DNA to stop replication), docetaxel, pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
injection, intravenous, infusion
Primary: To increase overall response rate (ORR)
Secondary: To determine the tolerability of pembrolizumab combined with induction chemotherapy and chemoradiation in patients with PNS SCC
Oncology